Dr. Dong Xu received his Ph.D. in Biostatistics from Columbia University. With over 20 years of expertise, he is a seasoned statistical leader in drug development across oncology, virology, immunology, and cardiovascular therapeutic areas. In addition to being proficient in drug regulations in various countries, his innovative approach to trial design and data analysis has contributed to 15+ successful global registrations. He has rich and unique leadership and collaboration experience in drug development.
Dr. Xu was the Head of Biostatistics for Bristol Myers Squibb Company, Asia Pacific Group and made important contributions to the successful registrations of the initial BLA and subsequent indications of Opdivo in China and worldwide. He also served as the senior vice president of biostatistics and data science at Ambrx.
Academically, he received the John Fertig Memorial Prize for outstanding dissertation in Biostatistics, Columbia, published more than 50 articles, oral presentations, and posters.